申请人:S. A. Labaz-Sanofi N.V.
公开号:US04400387A1
公开(公告)日:1983-08-23
Indolizine derivatives represented by the general formula: ##STR1## wherein R represents a straight- or branched-chain alkyl radical having from 1 to 8 carbon atoms, or a phenyl group non-substituted or bearing one or two substituents, which may be the same or different, selected from halogen atoms, for example fluorine, chlorine and bromine and from lower alkyl and alkoxy groups, for example methyl and methoxy and X.sub.1, X.sub.2 and X.sub.3, which may be the same or different, each represent hydrogen, chlorine, bromine or methoxy with the proviso that when they are identical X.sub.1, X.sub.2 and X.sub.3 are not simultaneously hydrogen. They possess an inhibitory activity with respect to the action of xanthine oxidase and of adenosine deaminase as well as an uricosuric action and can be used in the treatment of physiological disturbances consequent upon an excess of uric acid, upon disorders of the immunization system and as antiparasitic agents.
印度利津衍生物的一般化学式为:##STR1##其中R代表具有1至8个碳原子的直链或支链烷基基团,或者是一个非取代的苯基团或带有一个或两个取代基,这些取代基可以是相同的也可以是不同的,选择自卤素原子,例如氟、氯和溴,以及较低的烷基和烷氧基团,例如甲基和甲氧基,以及X.sub.1、X.sub.2和X.sub.3,这些可以是相同的也可以是不同的,每个代表氢、氯、溴或甲氧基,但当它们相同时,X.sub.1、X.sub.2和X.sub.3不能同时为氢。它们具有对黄嘌呤氧化酶和腺苷脱氨酶的抑制活性,以及尿酸排泄作用,可用于治疗由尿酸过多引起的生理紊乱,免疫系统紊乱和作为抗寄生虫剂。